Equillium presents pre-clinical data for oral EQ302 targeting IL-15/IL-21; analysts day held

Equillium, Inc.

EQ302 is an orally deliverable multi-cytokine inhibitor targeting IL-15 and IL-21.
Pre-clinical data show hydrocarbon staples improve GI stability while retaining cytokine inhibition.
Oral EQ302 reduced IL-15-induced IFN-g transcription in mouse small intestine.
Potential utility for Celiac Disease and inflammatory bowel disease highlighted.
Analyst and investor day held October 16, 2023, with pipeline and platform update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.